Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays
R. Fan1,†, W. Huang1,†, B. Luo2, Q. M. Zhang1, S. W. Xiao3, X. X. Xie2,†,*
1 Department of Histology & Embryology, School of Pre-clinical Medicine, Guangxi Chinese Medicine University, Nanning
2 Department of Histology & Embryology, School of Pre-clinical Medicine, Guangxi Medical University, Nanning
3 Surgery, First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region (China)
†These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2015, 36(3), 298–303; https://doi.org/10.12892/ejgo2636.2015
Published: 10 June 2015
Objectives: The purpose of this study was to determine the potential of cancer testis antigen OY-TES-1 as a vaccine for ovarian cancer (OC). Materials and Methods: A tissue microarray (TMA) containing 107 samples from OC tissues and 48 samples from OC adjacent tissues was analyzed by immunohistochemistry with the OY-TES-1 polyclonal antibody. The correlation between OY-TES-1 and clinic pathological traits of OC was statistically analyzed. Results: The expression of OY-TES-1 protein was found in 81% (87/107) of OC tissues and 56% (27/48) of OC adjacent tissues. The immunostaining intensity of OY-TES-1 in OC tissues was significantly higher than that in OC adjacent tissues tested (p = 0.040). OC adjacent tissues only demonstrated lower immunostaining intensity, whereas some of OC tissues presented higher immunostaining intensity and majority showed the heterogeneity of protein distribution. There was nostatistically significant correlation found between OY-TES-1 expression and any other clinicopathological traits such as age, FIGO stage, pathological grade, and histological type. Conclusions: OY-TES-1 was expressed in OC tissues with a high proportion, and some of OC tissues presented OY-TES-1 expression in high level vs OC adjacent tissues. OY-TES-1 could be an attractive target for immunotherapyfor OC in the future.